Source:http://linkedlifedata.com/resource/pubmed/id/17965555
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
4
|
pubmed:dateCreated |
2007-10-29
|
pubmed:abstractText |
Toxicity screening of a newly developed oral heparin derivative was carried out in twelve male cynomolgus monkeys (Macaca fascicularis), composed of three treatment and vehicle control groups. A newly orally active heparin derivative, developed by Seoul National University, was given to the treatment group at three doses with low (12.8 mg/kg), medium (89.6 mg/kg) and high (640 mg/kg) doses for 14 days. A treatment group did not show any change in body weights, hematological parameters (e.g., RBC, WBC, platelet, PDW, MPV, etc.) and serum biochemical parameters (e.g., AST, ALT, BUN, etc.) for 2 weeks compared with those of the vehicle control group. These findings indicated that the oral anticoagulant drug, a newly developed oral heparin derivative, did not have any toxic effect for 2 week in this study. The present study will be valuable in the proper interpretation for non-clinical study using cynomolgus monkeys in the development of a new drug of heparin derivative.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
0388-1350
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
32
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
411-20
|
pubmed:meshHeading |
pubmed-meshheading:17965555-Administration, Oral,
pubmed-meshheading:17965555-Animals,
pubmed-meshheading:17965555-Anticoagulants,
pubmed-meshheading:17965555-Deoxycholic Acid,
pubmed-meshheading:17965555-Drug Administration Schedule,
pubmed-meshheading:17965555-Heparin, Low-Molecular-Weight,
pubmed-meshheading:17965555-Macaca fascicularis,
pubmed-meshheading:17965555-Male,
pubmed-meshheading:17965555-Molecular Structure,
pubmed-meshheading:17965555-Toxicity Tests
|
pubmed:year |
2007
|
pubmed:articleTitle |
Toxicity screening after repeated dose of a newly developed oral heparin derivative in male cynomolgus monkeys.
|
pubmed:publicationType |
Letter,
Research Support, Non-U.S. Gov't
|